Guidance up, but the reason is not positive; chg.

DMRE Q2 slightly ahead on cost beats; guidance hiked on delayed disposals. Equity story now dominated by Apollo/Wecken stake sale (~91%); shares trade 74% below NAV. BUY, PT €0.80.